Introduction to the analysis of PET data in oncology.

Abstract:

:Several reviews on specific topics related to positron emission tomography (PET) ranging in complexity from introductory to highly technical have already been published. This introduction to the analysis of PET data was written as a simple guide of the different phases of analysis of a given PET dataset, from acquisition to preprocessing, to the final data analysis. Although sometimes issues specific to PET in neuroimaging will be mentioned for comparison, most of the examples and applications provided will refer to oncology. Due to the limitations of space we couldn't address each issue comprehensively but, rather, we provided a general overview of each topic together with the references that the interested reader should consult. We will assume a familiarity with the basic principles of PET imaging.

authors

Tomasi G,Aboagye EO

doi

10.1007/s10928-013-9307-3

subject

Has Abstract

pub_date

2013-08-01 00:00:00

pages

419-36

issue

4

eissn

1567-567X

issn

1573-8744

journal_volume

40

pub_type

杂志文章,评审
  • Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

    abstract::The utilisation of physiologically-based pharmacokinetic models for the analysis of population data is an approach with progressively increasing impact. However, as we move from empirical to complex mechanistic model structures, incorporation of stochastic variability in model parameters can be challenging due to the ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-015-9418-0

    authors: Tsamandouras N,Wendling T,Rostami-Hodjegan A,Galetin A,Aarons L

    更新日期:2015-08-01 00:00:00

  • Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components.

    abstract::The volume of distribution at steady state (Vss) of therapeutic proteins is usually assessed by non-compartmental or compartmental pharmacokinetic (PK) analysis wherein errors may arise due to the elimination of therapeutic proteins from peripheral tissues that are not in rapid equilibrium with the sampling compartmen...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-011-9209-1

    authors: Richter WF,Grimm HP,Theil FP

    更新日期:2011-10-01 00:00:00

  • Review on modeling anti-antibody responses to monoclonal antibodies.

    abstract::Monoclonal antibodies (mAbs) represent a therapeutic strategy that has been increasingly used in different diseases. mAbs are highly specific for their targets leading to induce specific effector functions. Despite their therapeutic benefits, the presence of immunogenic reactions is of growing concern. The immunogenic...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-014-9367-z

    authors: Gómez-Mantilla JD,Trocóniz IF,Parra-Guillén Z,Garrido MJ

    更新日期:2014-10-01 00:00:00

  • Evaluation of false positive rate based on exposure-response analyses for two compounds in fixed-dose combination products.

    abstract::We explored the type I error rate (false positive rate) associated with exposure-response (ER) analyses for two compounds in a fixed-dose combination product through simulations. In the simulations, at least one compound was assumed to be inactive, whereas the active compound followed E(max) model at different concent...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-011-9214-4

    authors: Zhu H,Wang Y

    更新日期:2011-12-01 00:00:00

  • Structural identifiability for mathematical pharmacology: models of myelosuppression.

    abstract::Structural identifiability is an often overlooked, but essential, prerequisite to the experiment design stage. The application of structural identifiability analysis to models of myelosuppression is used to demonstrate the importance of its considerations. It is shown that, under certain assumptions, these models are ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10928-018-9569-x

    authors: Evans ND,Cheung SYA,Yates JWT

    更新日期:2018-02-01 00:00:00

  • Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.

    abstract::The physiologically based pharmacokinetic (PBPK) models allow for predictive assessment of variability in population of interest. One of the future application of PBPK modeling is in the field of precision dosing and personalized medicine. The aim of the study was to develop PBPK model for amitriptyline given orally, ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9597-6

    authors: Tylutki Z,Mendyk A,Polak S

    更新日期:2018-10-01 00:00:00

  • Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.

    abstract::Changes in the reticulocyte subtype distribution (high, medium and low reticulocytes count (HR, MR, LR)) measured by flow cytometry following phlebotomy-induced stress erythropoiesis (abruptly dropping hemoglobin to 3-4 g/dl over 4-5 hr) and the pharmacodynamic (PD) relationship to the stimulated erythropoietin (EPO) ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0009-3

    authors: Al-Huniti NH,Widness JA,Schmidt RL,Veng-Pedersen P

    更新日期:2005-08-01 00:00:00

  • A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.

    abstract::HER2-positive breast cancer (BC) is a rapidly growing and aggressive BC subtype that predominantly affects younger women. Despite improvements in patient outcomes with anti-HER2 therapy, primary and/or acquired resistance remain a major clinical challenge. Here, we sought to use a quantitative systems pharmacological ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-020-09732-x

    authors: Franco YL,Ramakrishnan V,Vaidya TR,Mody H,Perez L,Ait-Oudhia S

    更新日期:2021-01-03 00:00:00

  • Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization.

    abstract::Regulatory authorities introduced procedures in the last decade for evaluating the bioequivalence (BE) for highly variable drugs. These approaches are similar in principle but differ in details. For example, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recommend differing regulatory c...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-019-09623-w

    authors: Endrenyi L,Tothfalusi L

    更新日期:2019-04-01 00:00:00

  • Structural identifiability and sensitivity.

    abstract::Ordinary differential equation models often contain a large number of parameters that must be determined from measurements by estimation procedure. For an estimation to be successful there must be a unique set of parameters that can have produced the measured data. This is not the case if a model is not structurally i...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-019-09624-9

    authors: Iliadis A

    更新日期:2019-04-01 00:00:00

  • A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.

    abstract::Drugs can affect the cardiovascular (CV) system either as an intended treatment or as an unwanted side effect. In both cases, drug-induced cardiotoxicities such as arrhythmia and unfavourable hemodynamic effects can occur, and be described using mathematical models; such a model informed approach can provide valuable ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9589-6

    authors: Cheung SYA,Parkinson J,Wählby-Hamrén U,Dota CD,Kragh ÅM,Bergenholm L,Vik T,Collins T,Arfvidsson C,Pollard CE,Tomkinson HK,Hamrén B

    更新日期:2018-06-01 00:00:00

  • A method of obtaining starting values of k(in) and k(out) for the indirect response models.

    abstract::A method based on the multivariate technique known as principal component analysis is proposed to obtain starting values for the rate constants of indirect response models. The method is not iterative and only requires standard deviation calculations for two quantities, which are simple functions of the measured pharm...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/b:jopa.0000029487.21238.5c

    authors: Mukherjee D,Hutmacher MM

    更新日期:2004-02-01 00:00:00

  • Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men.

    abstract::This study was designed to investigate ethnic differences in the pharmacokinetics (PKs) of moxifloxacin and its metabolites, M1 (sulfo conjugate) and M2 (acyl-glucuronate), among Japanese, Chinese, and Korean populations, following oral administration. We used a population PK modeling approach using data from a clinic...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9556-7

    authors: Kaneko M,Aoyama T,Ishida Y,Miyamoto A,Saito Y,Tohkin M,Kawai S,Matsumoto Y

    更新日期:2018-04-01 00:00:00

  • Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling.

    abstract::Multiple classes of antihypertensive drugs inhibit components of the renin-angiotensin-aldosterone system (RAAS). The primary physiological effector of the RAAS is angiotensin II (AngII) bound to the AT1 receptor (AT1-bound AngII). There is a strong non-linear feedback from AT1-bound AngII on renin secretion. Since AT...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9612-y

    authors: Gebremichael Y,Lahu G,Vakilynejad M,Hallow KM

    更新日期:2019-02-01 00:00:00

  • Performance in population models for count data, part I: maximum likelihood approximations.

    abstract::There has been little evaluation of maximum likelihood approximation methods for non-linear mixed effects modelling of count data. The aim of this study was to explore the estimation accuracy of population parameters from six count models, using two different methods and programs. Simulations of 100 data sets were per...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-009-9126-8

    authors: Plan EL,Maloney A,Trocóniz IF,Karlsson MO

    更新日期:2009-08-01 00:00:00

  • Understanding the linked kinetics of benzo(a)pyrene and 3-hydroxybenzo(a)pyrene biomarker of exposure using physiologically-based pharmacokinetic modelling in rats.

    abstract::3-hydroxybenzo(a)pyrene (3-OHBaP) in urine has been proposed as a biomarker of occupational exposure to polycyclic aromatic hydrocarbons. However, to reconstruct exposure doses in workers from biomarker measurements, a thorough knowledge of the kinetics of the benzo(a)pyrene (BaP) and 3-OHBaP given different routes of...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9338-9

    authors: Heredia-Ortiz R,Bouchard M

    更新日期:2013-12-01 00:00:00

  • Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics.

    abstract::The objective was to develop a physiologically-based pharmacokinetic (PBPK) model to characterize the whole-body disposition of paclitaxel (formulated in Cremophor EL and ethanol-Taxol®) in mice and to evaluate the utility of this model for predicting pharmacokinetics in other species. Published studies that reported ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9586-9

    authors: Zang X,Kagan L

    更新日期:2018-08-01 00:00:00

  • Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype.

    abstract::Mixture models are applied in population pharmacometrics to characterize underlying population distributions that are not adequately approximated by a single normal or lognormal distribution. In addition to obtaining individualized maximum a posteriori Bayesian post hoc parameter estimates, the subpopulation to which ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10928-006-9038-9

    authors: Kaila N,Straka RJ,Brundage RC

    更新日期:2007-04-01 00:00:00

  • Population in vitro-in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole.

    abstract::The aim of this study was to develop a population in vitro-in vivo pharmacokinetic model that simultaneously describe the absorption and accumulation kinetics of itraconazole (ICZ) and hydroxy-itraconazole (HICZ) in healthy subjects. The model integrated meta-models of gastrointestinal pH and gastrointestinal transit ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9555-8

    authors: Abuhelwa AY,Mudge S,Upton RN,Foster DJR

    更新日期:2018-04-01 00:00:00

  • Modeling cancer-immune responses to therapy.

    abstract::Cancer therapies that harness the actions of the immune response, such as targeted monoclonal antibody treatments and therapeutic vaccines, are relatively new and promising in the landscape of cancer treatment options. Mathematical modeling and simulation of immune-modifying therapies can help to offset the costs of d...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-014-9386-9

    authors: dePillis LG,Eladdadi A,Radunskaya AE

    更新日期:2014-10-01 00:00:00

  • Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.

    abstract::In the present pharmacokinetic/pharmacodynamic (PK/PD) evaluation, cortisol, total lymphocytes, and lymphocyte subpopulations were monitored following single oral doses of two oral formulations of 3 mg budesonide (BUD) (Dosage Forms A and B) in order to assess the differential effects that BUD may have on cortisol sup...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-006-9013-5

    authors: Stark JG,Werner S,Homrighausen S,Tang Y,Krieg M,Derendorf H,Moellmann H,Hochhaus G

    更新日期:2006-08-01 00:00:00

  • Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.

    abstract::Bootstrap methods are used in many disciplines to estimate the uncertainty of parameters, including multi-level or linear mixed-effects models. Residual-based bootstrap methods which resample both random effects and residuals are an alternative approach to case bootstrap, which resamples the individuals. Most PKPD app...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9343-z

    authors: Thai HT,Mentré F,Holford NH,Veyrat-Follet C,Comets E

    更新日期:2014-02-01 00:00:00

  • A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.

    abstract::The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma concentration data. In a next step, tissue and organ concentration time profiles in patients were predicted using the developed model. The WB-PBPK model w...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-016-9486-9

    authors: Sadiq MW,Nielsen EI,Khachman D,Conil JM,Georges B,Houin G,Laffont CM,Karlsson MO,Friberg LE

    更新日期:2017-04-01 00:00:00

  • Evaluation of mixture modeling with count data using NONMEM.

    abstract::Mixture modeling within the context of pharmacokinetic (PK)/pharmacodynamic (PD) mixed effects modeling is a useful tool to explore a population for the presence of two or more subpopulations, not explained by evaluated covariates. At present, statistical tests for the existence of mixed populations have not been deve...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1025564409649

    authors: Frame B,Miller R,Lalonde RL

    更新日期:2003-06-01 00:00:00

  • Estimating parameters of nonlinear dynamic systems in pharmacology using chaos synchronization and grid search.

    abstract::Bridging fundamental approaches to model optimization for pharmacometricians, systems pharmacologists and statisticians is a critical issue. These fields rely primarily on Maximum Likelihood and Extended Least Squares metrics with iterative estimation of parameters. Our research combines adaptive chaos synchronization...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-019-09629-4

    authors: Pillai N,Schwartz SL,Ho T,Dokoumetzidis A,Bies R,Freedman I

    更新日期:2019-04-01 00:00:00

  • A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin.

    abstract::The pharmacokinetics of cyclosporin (CsA) are unusual because of several heterogeneous features which include the presence of more than one conformer, considerable accumulation in erythrocytes and lipoproteins, extensive plasma protein binding, distribution into deep tissues, biliary secretion and hepatic clearance in...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1012295014352

    authors: Claret L,Iliadis A,Macheras P

    更新日期:2001-10-01 00:00:00

  • A reduction in between subject variability is not mandatory for selecting a new covariate.

    abstract::Population pharmacokinetic-pharmacodynamic analysis involves nonlinear hierarchical modelling where the mean response in a population and the variability in response from different sources are studied. It generally consists of two model hierarchies: a model for residual error and a model for heterogeneity termed betwe...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9256-2

    authors: Lagishetty CV,Vajjah P,Duffull SB

    更新日期:2012-08-01 00:00:00

  • A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling.

    abstract::Development of novel therapies for bone diseases can benefit from mathematical models that predict drug effect on bone remodeling biomarkers. Therefore, a bone cycle model (BCM) was developed that takes into consideration the concept of the basic multicellular unit and the dynamic equilibrium of bone remodeling. The m...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-015-9423-3

    authors: van Schaick E,Zheng J,Perez Ruixo JJ,Gieschke R,Jacqmin P

    更新日期:2015-08-01 00:00:00

  • Analysis of PK/PD risk factors for development of type 2 diabetes in high risk population using Bayesian analysis of glucose-insulin kinetics.

    abstract::This study was designed to investigate the pharmacokinetics/pharmacodynamics (PK/PD) risk factors preceding the onset of type 2 diabetes using a population-based Bayesian nonlinear hierarchical model to describe the glucose-insulin kinetics. One hundred fifty-two healthy subjects with a family history of type 2 diabet...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-009-9130-z

    authors: Lin CW,Veng-Pedersen P

    更新日期:2009-10-01 00:00:00

  • Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations.

    abstract::We used a previously developed physiologically based kinetic (PBK) model to analyze the effect of individual variations in metabolism and transport of cholesterol on pravastatin response. The PBK model is based on kinetic expressions for 21 reactions that interconnect eight different body cholesterol pools including p...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-014-9369-x

    authors: van de Pas NC,Rullmann JA,Woutersen RA,van Ommen B,Rietjens IM,de Graaf AA

    更新日期:2014-08-01 00:00:00